Sam Brownback said...

I think we should really look at a key issue, which is the economics of--you know, FDA and NIH can do all the work they ...

We are particularly concerned about the neglected diseases that you presented earlier on.

The old model of a billion dollars to develop a drug doesn't work in this category.

It doesn't seem like we're getting there yet with rare and neglected diseases.